Lindsey Shapiro, PhD,  science writer—

Vyne Therapeutics‘ experimental inhaled therapy VYN201 led to significant reductions in lung fibrosis and improvements in lung function in a mouse model of idiopathic pulmonary fibrosis (IPF), the company announced. “The data from this well-validated preclinical model of IPF clearly demonstrates VYN201’s potential to deliver a potent anti-inflammatory…

The use of aspirin, a common over-the-counter medicine, showed benefits in mouse and cell models of pulmonary fibrosis (PF) in a recent study, reducing evidence of scarring. The medication seemed to exert its beneficial effects by promoting a cellular maintenance process called autophagy, during which cells break down and…

Certain populations of immune monocytes and macrophages may be important targets of mesenchymal stem cell (MSC) therapy in idiopathic pulmonary fibrosis (IPF), according to a study. In an IPF mouse model, into-the-vein MSC treatment appeared to prevent monocytes from becoming a type of macrophage thought to promote the buildup…

The highest tested dose of bexotegrast, an anti-fibrotic treatment candidate from Pliant Therapeutics, was found to best — and safely — improve lung function in people with idiopathic pulmonary fibrosis (IPF), outperforming all lower doses in a Phase 2a trial. Three-month data from the INTEGRIS-IPF trial (NCT04396756)…

TXR-1002, Aria Pharmaceuticals’ investigational candidate for idiopathic pulmonary fibrosis (IPF), effectively prevented the buildup of scar tissue, or fibrosis, in the lungs of a rat model of the disease. Its effectiveness was comparable to that of the approved IPF therapy, Ofev (nintedanib) and was consistent with findings…

A test by Veracyte can be used to predict which patients with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), are more likely to experience progressive decline in their lung function, according to new data. Called the Envisia Genomic Classifier, the test works by identifying the genomic…

The cellular aging of a group of cells called alveolar type 2 pneumocytes — which work to promote airway stability, and play a key role in lung repair after injury — may be responsible for driving pulmonary fibrosis (PF). That’s according to new findings from a team led by…

The first patient has been enrolled in a Phase 3 clinical trial of Tyvaso (treprostinil) inhalation solution for patients with idiopathic pulmonary fibrosis (IPF), according to the therapy’s developer, United Therapeutics. Called TETON 2 (NCT05255991), the trial will evaluate the treatment’s efficacy against a placebo in about…

NP-120 (ifenprodil), an investigational treatment for idiopathic pulmonary fibrosis (IPF) and chronic cough, continues to demonstrate an ability to preserve lung function and ease cough, according to analyses of secondary goals in a Phase 2a trial. Most of these analyses related to patient-reported outcomes, supplementing positive top-line data from…

Accord Healthcare has released a generic version of Esbriet (pirfenidone) for people in the U.S. with idiopathic pulmonary fibrosis (IPF). First approved by the U.S. Food and Drug Administration (FDA) in January, the treatment is now available and ready to be shipped, according to Accord. “We’re proud…